Literature DB >> 32067967

Examining indicators of early menopause following opportunistic salpingectomy: a cohort study from British Columbia, Canada.

Gillian E Hanley1, Janice S Kwon2, Jessica N McAlpine2, David G Huntsman3, Sarah J Finlayson2, Dianne Miller2.   

Abstract

BACKGROUND: The fallopian tube may often be the site of origin for the most common and lethal form of ovarian cancer, high-grade serous ovarian cancer. As a result, many colleges of obstetrics and gynecology, which include the American College of Obstetricians and Gynecologists, are recommending surgical removal of the fallopian tube (bilateral salpingectomy) at the time of other gynecologic surgeries (particularly hysterectomy and tubal sterilization) in women at general population risk for ovarian cancer, collectively referred to as opportunistic salpingectomy. Previous research has illustrated no increased risk of complications after opportunistic salpingectomy. However, most studies that have examined potential hormonal consequences of opportunistic salpingectomy have had limited follow-up time and have focused on surrogate hormonal markers.
OBJECTIVE: We examine whether there are differences in physician visits for menopause and filling a prescription for hormone replacement therapy among women who undergo opportunistic salpingectomy in the population of British Columbia, Canada. STUDY
DESIGN: We identified all women who were ≤50 years old in British Columbia who underwent opportunistic salpingectomy from 2008-2014. We compared women who underwent opportunistic salpingectomy at hysterectomy with women who underwent hysterectomy alone and women who underwent opportunistic salpingectomy for sterilization with women who underwent tubal ligation. We used Cox Proportional hazards models to model time to physician visits for menopause and for filling a prescription for hormone replacement therapy. We calculated adjusted hazards ratios for these outcomes and adjusted for other gynecologic conditions, surgical approach, and patient age. We performed an age-stratified analysis (<40, 40-44, 45-49 years) and conducted a sensitivity analysis that included only women with ≥5 years of follow up.
RESULTS: We included 41,413 women in the study. There were 6861 women who underwent hysterectomy alone, 6500 who underwent hysterectomy with opportunistic salpingectomy, 4479 who underwent hysterectomy with bilateral salpingo-oophorectomy, 18,621 who underwent tubal ligation, and 4952 who underwent opportunistic salpingectomy for sterilization. In women who underwent opportunistic salpingectomy, there was no difference in time to the first physician visit related to menopause for both women who underwent hysterectomy with opportunistic salpingectomy (adjusted hazard ratio, 0.98; 95% confidence interval, 0.88-1.09) and women who underwent opportunistic salpingectomy for sterilization (adjusted hazard ratio, 0.92; 95% confidence interval, 0.77-1.10). There was also no difference in time to filling a prescription for hormone replacement therapy for women who underwent hysterectomy with opportunistic salpingectomy or opportunistic salpingectomy for sterilization (adjusted hazard ratio, 0.82; 95% confidence interval, 0.72-0.92; and adjusted hazard ratio, 1.00; 95% confidence interval, 0.89-1.12; respectively). In contrast, we report significantly increase hazards for time to physician visit for menopause (adjusted hazard ratio, 1.95; 95% confidence interval, 1.78, 2.13) and filling a prescription for hormone replacement therapy (adjusted hazard ratio, 3.80; 95% confidence interval, 3.45, 4.18) among women who underwent hysterectomy with bilateral salpingo-oophorectomy. There were no increased hazards for physician visits for menopause or initiation of hormone replacement therapy among women who underwent opportunistic salpingectomy in any of the age-stratified analyses, nor among women with at least 5 years of follow up.
CONCLUSION: Our results reveal no indication of an earlier age of onset of menopause among the population of women who underwent hysterectomy with opportunistic salpingectomy and opportunistic salpingectomy for sterilization as measured by physician visits for menopause and initiation of hormone replacement therapy. Our findings are reassuring, given that earlier age at menopause is associated with increased mortality rates, particularly from cardiovascular disease.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  bilateral salpingectomy; hysterectomy; menopause; ovarian cancer; sterilization

Year:  2020        PMID: 32067967     DOI: 10.1016/j.ajog.2020.02.005

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  5 in total

1.  Opportunistic salpingectomy between 2011 and 2016: a descriptive analysis.

Authors:  Gillian E Hanley; Jin Niu; Jihee Han; Sharon Fung; Heather Bryant; Janice S Kwon; David G Huntsman; Sarah J Finlayson; Jessica N McAlpine; Dianne Miller; Craig C Earle
Journal:  CMAJ Open       Date:  2022-05-31

2.  Bone health after RRBSO among BRCA1/2 mutation carriers: a population-based study.

Authors:  Helena Abreu do Valle; Paramdeep Kaur; Janice S Kwon; Rona Cheifetz; Lesa Dawson; Gillian E Hanley
Journal:  J Gynecol Oncol       Date:  2022-03-30       Impact factor: 4.756

3.  Survey: acceptability of opportunistic bilateral salpingectomy in Flanders.

Authors:  A S Maryns; A Makar; T Hamerlynck; B De Vree; P Tummers; W A A Tjalma
Journal:  Facts Views Vis Obgyn       Date:  2021-09

4.  Outcomes From Opportunistic Salpingectomy for Ovarian Cancer Prevention.

Authors:  Gillian E Hanley; Celeste Leigh Pearce; Aline Talhouk; Janice S Kwon; Sarah J Finlayson; Jessica N McAlpine; David G Huntsman; Dianne Miller
Journal:  JAMA Netw Open       Date:  2022-02-01

5.  Comparing options for females seeking permanent contraception in high resource countries: a systematic review.

Authors:  Rebecca Gormley; Brian Vickers; Brooke Cheng; Wendy V Norman
Journal:  Reprod Health       Date:  2021-07-20       Impact factor: 3.223

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.